A novel Selective BCL2 inhibitor with limited immune suppression and improved safety compared to venetoclax

Dec 19

Written By Guest User

A novel Selective BCL2 inhibitor with limited immune suppression and improved safety compared to venetoclax

Download Poster

Guest User

A Novel, wild-type sparing pan-EGFR Inhibitor (ZE77-0273) with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC

Therapeutic Targeting of FLT3 gate keeper mutation with E2082-0047 in traditional and a novel Immunocompetent murine adoptive transfer model of AML